



EY Entrepreneur of the year-2013



FROST & SULLIVAN 2013 BEST PRACTICES AWARD



Business today/YES bank Excellence Awards-2013



Date: 16<sup>th</sup> March, 2023

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

Dear Sir/Madam,

In accordance with the requirements of regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, the company would like to announce acquisition of nine dermatology brands from Dr.Reddy's Laboratories Ltd. The further details are tabulated in Annexure I.

The details of the same will also be uploaded on the website of the Company.

Thanking You,

**For Eris Lifesciences Limited**

**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**  
**Membership No: A26493**

**Encl: As above**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



Annexure I

<b>Acquisition (including agreement to acquire):</b>		
a)	Name of the target entity, details in brief such as size, turnover etc.	<p><u>Target Entity:</u> - Part of the dermatology portfolio of Dr.Reddy's Laboratories Ltd. by way of acquisition of 9 (Nine) trademarks along with their applicable line extensions (collectively referred to as "<b>Brands</b>") by Eris Lifesciences Limited.</p> <p><u>Consideration:</u> - INR 275 Crores.</p>
b)	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	<p>The acquisition would not be categorized as 'related party transaction' and none of the promoter/promoter group/ group companies have any interest in the acquisition.</p> <p>The transaction is at arms-length.</p>
c)	Industry to which the entity being acquired belongs;	<p>Pharmaceutical Industry.</p> <p>Only a part of the dermatology portfolio is being acquired through the Transaction.</p>
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The transaction helps augment and expand the cosmetic dermatology business of the Company by way of expansion in the product offerings
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
f)	Indicative time period for completion of the acquisition	The Transaction is to stand completed on or before 31 <sup>st</sup> March 2023
g)	nature of consideration -whether cash	Cash Consideration

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



	consideration or share swap and details of the same;							
h)	cost of acquisition or the price at which the shares are acquired	INR 275 crores						
i)	percentage of shareholding / control acquired and / or number of shares acquired;	Not applicable						
j)	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p><u>Brief background:</u> - The transaction is related to formulations falling primarily in the cosmetic dermatology segment.</p> <p><u>Date of Incorporation:</u> - Not applicable</p> <p><u>History of Turnover of the Brands (as per AWACS):</u> INR Crore</p> <table border="1"> <thead> <tr> <th>FY 20- 21</th> <th>FY 21- 22</th> <th>FY 22-23 (Till Feb'23)</th> </tr> </thead> <tbody> <tr> <td>52.80</td> <td>61.60</td> <td>62.10</td> </tr> </tbody> </table> <p><u>Country:</u> - The Transaction is intended for India business.</p>	FY 20- 21	FY 21- 22	FY 22-23 (Till Feb'23)	52.80	61.60	62.10
FY 20- 21	FY 21- 22	FY 22-23 (Till Feb'23)						
52.80	61.60	62.10						

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867